Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL AND CHLORTHALIDONE versus RENESE.
ATENOLOL AND CHLORTHALIDONE vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atenolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (atenolol 50 mg/chlorthalidone 25 mg) orally once daily. May be increased to 2 tablets once daily.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Atenolol: 6-7 hours (prolonged to 14-27 hours in severe renal impairment); Chlorthalidone: 40-60 hours (allows once-daily dosing).
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Atenolol: ~50% eliminated unchanged in urine; Chlorthalidone: ~50-70% eliminated unchanged in urine, remainder as metabolites via renal and biliary routes (<10% fecal).
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic